



**2nd International Longevity Policy & Governance Summit
11 November 2020**

Longevity Week 9-12 November, 'The Age of Resilience'

Theme

The theme for the 2nd International Longevity Policy & Governance Summit is Health is:

*Health Our Greatest Societal Asset:
Multi-Stakeholder Global Collaboration for Health and Economic Resilience*

Context

A recent [McKinsey report](#) estimates that the cost of ill health was about 15 percent of global real GDP in 2017, and that the COVID-19 pandemic and its repercussions will reduce global GDP by 3 to 8 percent in 2020. It concludes that long-term prevention and health promotion cannot simply be left to healthcare providers or healthcare systems, and that “it is quite literally everybody’s business.”

So then, preventative health needs to be at the centre to build up health and economic resilience post-pandemic. Indeed, arguably the even bigger crisis looming is the chronic disease ‘epidemic’- delays in cancer diagnosis and backlogs of cases have all increased with people fearful of seeing doctors and going to hospitals, only adding to the significant burden that existed *before* the pandemic. The recent [OpenSafely study](#) showed that people with obesity, diabetes, coronary heart disease and hypertension, were much more likely to die from COVID-19, all mostly preventable diseases linked to social inequalities too.

There is no doubt that the fracture lines of society have been horribly exposed by COVID-19, with the elderly, those in the poorest health and living in deprived communities hardest hit.

So far governments around the world have injected [over \\$9 trillion to save the global economy](#). While governments and healthcare systems wrestle with the immediate crisis, businesses have had to act quickly too.

Rather perversely, then, it seems many positives are unfolding that are powerful and compelling. For one thing, leaders have a once-in-a-lifetime opportunity to reshape how societies can provide healthier, better, greener, and more equitable outcomes for all, an opportunity that the World Economic Forum has hailed as the [Great Reset](#). The cornerstone of this Reset is a new 'stakeholder capitalism', a more socially responsible version of capitalism to restore social justice and ensure that wealth is distributed more fairly amongst all stakeholders in society.

Professor Baron Peter Piot KCMG, Director of the London School of Hygiene & Tropical Medicine and Special Advisor to the President of the European Commission on research and innovation for COVID-19, says: "COVID-19 illustrates how important it is to prevent the development of obesity, diabetes, and cardiovascular disease through healthy lifestyles. We live in a completely obesogenic environment. In order to have a better future for everybody, we need to not only work on our own health but also respect the health of the planet."

The power of technology to help solve the global pandemic has emerged with startling clarity. AI is helping researchers analyse gigantic datasets to forecast the spread of the virus, to provide an early warning system for future pandemics and to identify vulnerable populations needing help. It has also accelerated the pace with which we are identifying many promising vaccines.

Very early on it was clear that COVID-19 does not treat all age groups equally, and that many of the expected interventions such as vaccines, therapeutic, and symptomatic treatments will not work as well in the elderly.

The link between the elderly and risk of COVID-19 appears to be increased baseline inflammation, called 'inflammaging' that is present in older individuals, according to the [latest research](#). Inflammation is implicated in chronic diseases and the ageing process itself,

so it is also not surprising that much of this COVID-19 research is led by many scientists who are experts in longevity and the science of ageing.

But while AI is being harnessed to accelerate research into vaccines and treatments for COVID-19, so should it be applied with the same urgency to help prevent chronic diseases, as well as ageing itself, to keep us healthy for longer. Research into ageing biomarkers is expected to furnish important insights into how we can stay healthy and measure the effectiveness of interventions targeting the wider determinants of health.

Suggested Programme (To be confirmed)

Overall chair, Tina Woods, CEO, Longevity International

13:00-13:15 Keynote: What COVID-19 is teaching us about global health

- Professor Baron Peter Piot KCMG, Director of the London School of Hygiene & Tropical Medicine and Special Advisor to the President of the European Commission on research and innovation for COVID-19

13:15-13:30: Global Analysis: COVID-19 Risk and Safety Rankings

- Dmitry Kaminskiy, Managing Partner, Deep Knowledge Group: key findings from [COVID-19 Regional Safety Assessment: Big Data Analysis of 250 Countries and Regions COVID-19 Safety Ranking and Risk Assessment](#), ranking the economic, societal and health stability of 200 regions globally

13:30-13:50: COVID-19 and Healthy Longevity: the Biomedical Perspective (Panel)

- Dr Lynne Cox (Oxford University), Dr Alex Zhavoronkov (Insilico Medicine), Dr Richard Siow (ARK), Brian Kennedy, (Singapore); Professor Linda P. Fried (Dean and DeLamar Professor of Public Health, Senior Vice President, Columbia University Medical Center, USA)
- Moderated by Cassandra Coburn, Editor, Lancet Healthy Longevity with 5-10 min Q & A with audience

13:50-14:10: COVID-19 and Healthy Longevity: the Business Perspective (Panel)

- John Godfrey (Corporate Affairs director, Legal & General) or Andy Briggs (CEO, Phoenix Group, Co-Chair UK Longevity Council); Matthew Fell, Policy Director, CBI; TBC World Economic Forum; Sergey Young, Longevity Vision Fund

- Moderated by Professor Andrew Scott, London Business School with 5-10 min Q & A with audience

14:10-14:30: COVID-19 and Healthy Longevity: the Policy Perspective (Panel)

- Victor Dzau, National Academy of Medicine, Global Healthy Longevity Grand Challenge; Rt Hon Damian Green MP, Chair, All-Party Parliamentary Group for Longevity; Kazumi Nishikawa, Director, Healthcare Industries Division, Ministry of Economy, Trade and Industry of Japan, Member of the Global Future Council for Human Enhancement and Longevity, World Economic Forum)
- Moderated by Tina Woods with 5-10 min Q & A with audience

14:30-14:40: Break

14:40-15:40 -Country reflections on legacy from Covid-19 and healthy longevity

- 15:40-15:55: UK: Experience from All-Party Parliamentary Group for Longevity, Geoff Filkin/Tina Woods
- 15:55-16:10: USA: Experiences from Kitalys Institute/National Academy of Medicine, Zan Fleming/Adriene Berg/Victor Dzau
- 16:10-16:25: Asia: Experience from Singapore or Japan. TBC
- 16:25-16:40: Europe: Experience from Switzerland or Israel. TBC

16:40- 17:00: Round-Up of Reflections and Q & A with audience

- Closing remarks by WHO, CDC or European Parliament
- Thank you and Close by Tina Woods